In More Pain? Blame the Weather – and Climate Change

By Crystal Lindell

On Wednesday, three people I know all had a migraine. My mom also told me that her hip joint was suddenly much more painful than normal. And the intercostal neuralgia in my ribs hurt so bad that I spent most of the day in bed.

The next day, the temperature here in northern Illinois suddenly spiked to 53 degrees Fahrenheit – an unusual occurrence for Januar. Then the rain started and never really stopped.

The random spike to 50 degree weather – when most people here still have their Christmas lights up – felt almost ominous. And it seems our bodies agreed.   

If we lived in the 1800s, all of us could have served as our town’s meteorologist, accurately predicting both temperature changes and precipitation.

But here in 2026, many people still don’t even connect their pain flares to weather changes. And I still hear doctors dismiss the idea that weather can impact pain.

As someone who lives with chronic pain, I think the connection is obvious. I can tell you almost down to the hour when it’s going to snow. I have learned to plan my rest days around rapid temperature changes in the forecast. And when it’s sunny and clear, I sometimes find myself wondering if I have somehow been cured – because I feel so little pain!

The thing is, the reason we had a 53 degree temperature spike in the middle of winter in northern Illinois is likely due to climate change. While the warm front may have come in regardless, just how warm it got was likely amplified by global warming.

In fact, the shifting global climate means we are all experiencing weather fluctuations and temperatures that had previously been considered rare.

And our bodies have noticed.

A recent story by Inside Climate News discusses the link.

"Global warming is bringing more heatwaves and an atmosphere that sucks up more moisture to feed storms. Those thermodynamic effects of climate change often have more clear ties to pain," wrote Chad Small, a PhD student in Atmospheric and Climate Science at the University of Washington. 

“For example, gout sufferers living in Arizona—which will continue to get hotter and dryer as global temperatures increase—will likely experience worse pain due to more frequent and severe instances of dehydration driven by the increasing temperatures and aridity. That’s on top of the exacerbation of the pain by the heat itself.” 

In 2023, The University of Pennsylvania published an article titled, "Why climate change might be affecting your headaches" in Penn Medicine News.

“Rising global average temperature and extreme weather events are likely to become more frequent or more intense,” they wrote. “Experts suggest that the stress of these events can trigger headaches.”

Society at large seems to still be in denial about all of this though, at least in my experience.

For example, when the weather changes, people who get migraines don’t get more sick days or easier access to government assistance.

And while weather changes are causing more pain flares, government regulators and health officials still limit access to opioid pain medication.

Not to mention the lack of social accommodation. Friends and family aren’t more understanding about the increase in pain because of climate change. In fact, most people aren’t even more forgiving of their own bodies in that situation.

The ableism at the root of our culture in the United States still expects people to push through the pain and show up anyway – and that social pressure only increases when someone’s pain flares get more frequent.

In other words, the more climate change increases pain, the less accepting people are of it. Perhaps that’s because many are still in denial that climate change even exists.

Unfortunately, all indications are that climate change is only going to continue getting worse, which means the pain it causes will do the same.

If we are going to endure it, we are going to have to offer grace to others and ourselves when that pain shows up in our bodies.

We can’t control the weather, but we can control how we endure it.  

Chronic Pain and Complications Common After Outpatient Surgery

By Pat Anson

Outpatient surgeries are often touted for their convenience and cost savings. The surgeries are often minimally invasive, less painful, reduce trauma and recovery time, and save patients (and insurers) thousands of dollars because they don’t have to spend a night or two in the hospital in post-op care. 

But two new studies in the UK – where outpatient procedures are called “day-case” surgeries – show the benefits of outpatient surgery are not universal and often make pre-existing pain conditions worse.

The studies, published here and here in the journal Anaesthesia, involved nearly 17,500 patients, and were conducted by a team of researchers at the NHS Foundation Trust and University Hospitals Plymouth. 

In the first study, researchers found that 1 in 8 patients (11.8%) who had day-case surgery did not go home the same day and were admitted to hospital for various complications. For some patients who had prostate procedures (including those for cancer and benign prostate growth), the hospital admission rate was higher than 50%.

In the second study, one in 14 patients (7.2%) developed chronic pain or had their pain worsen at the surgery site. Some procedures had higher rates of chronic pain after 3 months, including orthopaedic (13.4%) and breast (10%) surgeries. Patients with chronic post-surgical pain also had lower quality of life scores than they did before the surgeries.

To be fair, many of the patients in the studies had chronic pain before their surgeries. Pain was already present at the surgery site in 39% of patients and was moderately severe. Chronic pain elsewhere in the body was also common. About one in four patients had opioid prescriptions prior to their surgeries, and a little over one in 10 used opioids daily. 

These were the first studies of their kind in the UK, and fill an important gap in information about the outcomes of outpatient surgery. Because the UK’s National Health Service seeks to have 85% of eligible elective operations be done as day-case surgeries, researchers expect the outpatient workload to increase and the numbers of patients with chronic post-surgical pain to also grow..

“In summary, this large multicentre UK observational study on day-case surgery provides valuable new insights into a key patient group. We have shown that chronic pain is prevalent within this cohort, with a significantly higher burden than the general population,” the authors found.

“While most patients undergoing day-case surgery were discharged on the same day, the rate of unplanned inpatient admissions was unacceptably high, at twice the national target. This finding underscores a critical area for improvement, as reducing unplanned admissions would enhance the efficiency of day-case surgery and improve outcomes for patients. We highlight the complexity of day-case surgery, where even procedures that are generally seen as straightforward can still carry potential risks, especially for certain patient groups.”

Previous studies have found that female patients had higher rates of chronic post-surgical pain. The new studies found no difference in outcomes between males and females overall, but did show that gynaecological and breast surgeries (almost all female patients) had higher rates of chronic post-surgical pain. This suggests that medical specialties –  rather than being female –- were behind the increased risk.

The studies also found that wealthier patients were less likely to have chronic post-surgical pain compared to the poorest ones. Patients of Asian, Black and mixed ethnicity were also more likely to report chronic post-surgical pain, which may be due to healthcare inequities and cultural difference in pain perception.

Utah Launches AI-Powered Prescription Refills

By Crystal Lindell

Utah is testing a new AI-powered prescription drug service that allows people to skip seeing the doctor if they need a medication refilled for some chronic conditions.

The program is powered by Doctronic, a telehealth service that uses artificial intelligence to act in the role of a doctor, asking patients questions that are typically asked during a refill appointment.

The renewal process will take less than five minutes and Doctronic will charge just $4 for the service.

“If you’re in the state of Utah and you need let’s say a statin renewed because you have high cholesterol and you don’t have any more renewals left on your prescription, but you’ve already been taking that statin, you can talk to our AI,” Matt Pavelle, Co-CEO of Doctronic, told ABC4 in Salt Lake City

“It’s going to lead you through the process as a human doctor would, ask all of the right questions, look up all the right interactions, make sure that it’s safe for you…to receive that renewal. It will approve that and send it to a pharmacy in Utah for you.”

The list of medications that Doctronic will refill is limited. The strongest pain relievers you can get are prescription strength acetaminophen and NSAIDs. Other medications used by people with chronic conditions like diabetes are also unavailable.

“The program does not fill prescriptions for controlled substances, such as opioids or ADHD medications, nor are injectables eligible, such as insulin or semaglutide/weight-loss drugs,” a spokesperson for the Utah Department of Commerce told PNN.

Maybe Utah’s program will work as they claim and using it will be even better than talking or seeing a human doctor. But I’m skeptical.

A program like this has the potential to help patients, but it comes with a lot of questions about how it will work in practice – especially given how horrible customer service AI bots have been in general. From personal experience, I can tell you that they are often impossible to communicate with.

I also worry about how accurate Doctronic is, given that other AI bots like ChatGPT can have an error rate of 52%. When it comes to medical decisions, that kind of error rate can be deadly. 

In case of a problem or error with a prescription, Doctronic could be held liable. According to ABC4, Doctronic is covered by a malpractice insurance policy

AI prescription refills could save patients from the cost and hassle of a doctor’s appointment, but if a program like this really takes off, I am certain that the companies running them will then increase the price of each AI appointment. 

In the end, if it was safe to continue prescribing a medication without checking in with a human doctor, the human doctor could easily allow for multiple refills..

And if a human doctor is not needed as part of the equation, why is an AI doctor even needed?

Theoretically, if human doctors are not needed, commonly renewed medications could just have a check-in questionnaire that patients fill out when they need more refills. A doctor would only get involved if any of the responses warranted it.

I would wager such a program would be significantly more accurate, but also significantly more difficult to launch. The lack of a buzzy AI angle would probably be a turn off for both lawmakers and medical professionals.  

There’s also the issue of losing the patient-to-doctor interaction, where other health issues are often flagged and treated. This program all but eliminates that possibility. 

It will be interesting to see how patients and doctors respond to the Doctronic program, and whether they like actually using it. I fully support making healthcare and prescriptions more affordable and accessible. I am just not convinced that an AI chatbot is the best way to achieve either of those goals. 

Excess Weight Raises Risk of Lower Back Pain

By Pat Anson

If you suffer from lower back pain, chances are you’ve had a doctor or someone in your life suggest that you lose some weight. Back pain is commonly associated with a sedentary lifestyle, lack of exercise, and a high body mass index (BMI).

But how much weight is too much? How many pounds do you have to lose to reduce the risk of back pain?

A large new study at Boston University provides some surprising answers. Researchers there reviewed the medical records of over 110,000 adults, aged 18 or older, who visited an urban teaching hospital for outpatient care. Their weight, height, age and sex were then used to calculate their body mass index.  

Not surprisingly, the higher the BMI, the higher the risk was of having lower back pain (LBP). For people with a BMI in the range of 18-35, researchers found that every increased unit of BMI (about 10 pounds), raises the risk of lower back pain by 7%. 

What’s surprising about that finding is that it includes people with a BMI of 18 to 24.9, which is considered a healthy weight, as well as people who are overweight (25 to 29.9 BMI) or obese (30-34.9 BMI).

People with a BMI above 35, which is considered severe obesity, and those with a BMI above 40 (morbid or extreme obesity), must have an even higher risk of lower back pain, right?

Wrong.

Researchers found that for those with a BMI above 35, the prevalence of low back pain did not increase but stayed the same.

Of course, that doesn’t mean you should pack on extra pounds and become morbidly obese to lower your risk of back pain. But it suggests that at a certain point, excess weight stops being a driving factor in LBP and that BMI is an imperfect tool to measure risk. 

Not everyone with a high BMI will experience LBP and being at a healthy weight will not protect you from back pain. About 80 percent of adults experience low back pain at some point in their lives, making it a nearly universal experience, regardless of weight. LBP is the most common cause of job-related disability and a leading contributor to missed work days. 

A number of other factors contribute to LBP, such as smoking, alcohol use, poor sleep and psychological stress. Regular exercise and a healthy lifestyle can help lower your risk of LBP, but they won’t prevent it. 

“Our study strongly suggests that maintaining a healthy weight or BMI is likely helpful at avoiding low back pain,” says lead author Michael Perloff, MD, an Assistant Professor of Neurology at Boston University and Director of Pain Medicine at Boston Medical Center.

“Low back pain is one of the most common complaints patients have for their medical providers. While medications, formal physical therapy and other treatments can help, correcting risk factors, such as smoking or deconditioning, also help LBP.”

The findings appear online in the journal Pain Medicine.

Other studies have found that having a few extra pounds is not harmful to overall health. Some older adults with the lowest risk of early death had BMIs of 27 to 28, which falls into the “overweight” range; while many older adults with the highest mortality risk have BMIs under 22 — which would be considered a healthy weight.

While losing weight won’t prevent low back pain, it could help lower your pain levels. A 2018 study found that people who lose 10% of their body weight had less overall body pain. They also had better mental health, improved cognition and more energy. Men in particular showed improvements in their energy levels when they lost weight.

DEA Cuts Oxycodone Supply, But Raises Production of Morphine in Surprise Move

By Pat Anson

The Drug Enforcement Administration is moving ahead with its plan to reduce the supply of oxycodone by over 6% in 2026, while at the same time significantly raising its production quota for morphine. There will be small reductions in the supply of hydrocodone, codeine and other Schedule II opioids this year.

The move to increase the supply of morphine by 10.5% is surprising, as the agency proposed cutting morphine production by over half a percent a little over a month ago. 

The DEA officially announced its plans January 5 in the Federal Register, 35 days after a December 1 deadline set for the agency in the Controlled Substances Act (CSA). Under the CSA, the DEA has broad legal authority to set annual aggregate production quotas (APQs) for opioids and other controlled substances. 

The December 1 deadline is important because it gives the pharmaceutical industry time to prepare for the coming year by adjusting drug manufacturing and distribution schedules. The DEA’s chronic failure to meet that deadline in previous years has contributed to shortages, according to drug makers.

Over 5,000 public comments were received by the DEA in response to the agency’s initial APQs for 2026. Most comments pleaded with the agency not to make any further cuts in the supply of opioids, many of which are already in short supply at pharmacies and hospitals. 

“I oppose cutting production for controlled medications at this time as there is already a shortage for many of these medications and patients are often not able to obtain their prescriptions. Cutting production during a shortage will only exacerbate the problem and increase patient suffering,” Hannah Khalil wrote in a public comment echoed by many others. 

The DEA, however, was dismissive of claims about opioid shortages, saying it was not responsible for them.

“Drug shortages may occur due to factors outside of DEA's control such as manufacturing and quality problems, processing delays, supply chain disruptions, or discontinuations,” the DEA said. “Currently, FDA has not listed on its Drug Shortage website any nationwide shortages of oxycodone and hydrocodone products.”

While it is true the FDA does not currently have oxycodone or hydrocodone on its shortage list, the American Society of Health-System Pharmacists (ASHP) has listed both opioids on its shortage list since 2023. Limited supplies of oxycodone and hydrocodone are available from some manufacturers, according to the ASHP, while others have the medications on back order.

The difference between the FDA and ASHP shortage lists is that the FDA relies on drug manufacturers to report shortages, while the ASHP proactively surveys both pharmacies and drug makers about their inventories. That arguably makes it superior to the FDA’s methodology.

Ironically, the DEA itself has challenged the reliability of the FDA’s drug shortage list.

“DEA has made it clear it does not trust FDA’s information, as it does not consider many of the shortages that FDA verifies to be legitimate,” the General Accountability Office (GAO) said in a 2015 audit report. “They do not believe FDA appropriately validates or investigates the shortages.”

Increased Morphine Production

The DEA offered no explanation for the increase in morphine production. The production quota for morphine is 10.55% higher than last year's quota and the highest amount since 2021.

One likely reason for the DEA’s decision is that the FDA recently added morphine tablets and injectable morphine solutions to its shortage list, due to discontinuations and short supplies. The ASHP has listed morphine in shortage for several months. 

Morphine solutions and other injectable opioids are an important resource in hospitals, emergency rooms and surgery centers, where they are used in post-op care, sedation and anesthesia.

Morphine tablets are most often used to treat severe chronic pain.

I fear there will be continued shortages resulting in many patients suffering from the DEA’s quota decisions.
— Dr. Lynn Webster, pain management expert

“In 2025, there were major shortages of morphine immediate release (15-mg, 30-mg tablets) and morphine extended release (mostly 30-mg tablets) that lasted 3-4 months and were disruptive to care. I mentioned morphine in my personal, submitted comments (to the Federal Register),” said Chad Kollas, MD, a palliative care physician in Florida.

“I suspect that others also complained about last year’s morphine shortages, which may have led to the increase in production of morphine in 2026. It is also the cheapest of the traditional opioids, which may have played a role in the decision. I’m disappointed that they held the line on the oxycodone reduction.”

“I don't know why the DEA would reduce oxycodone while increasing the morphine quota. It seems illogical since there are reports that both are in shortage at the clinical level,” says Lynn Webster, MD, a pain management expert and former president of the American Academy of Pain Medicine. “I fear there will be continued shortages resulting in many patients suffering from the DEAs quota decisions.  

“They know patients are struggling to get access to both medications but they may think oxycodone is more likely to be abused than morphine. It appears they are trying to tell providers what they should prescribe. Yet they are not supposed to be involved in determining how medicine is practiced. Whether intentional or not, that is exactly what they are doing.”

Even with this year’s increase in morphine production, DEA has reduced the supply of morphine by over 63% since 2015. Steep declines have also been made in quotas for hydrocodone (-73%), oxycodone (-71%), and codeine (-70%) over the past decade.  

The DEA began cutting the opioid supply in response to pressure from Congress and anti-opioid activists, who claimed that prescription opioids were responsible for soaring overdose rates. While that claim has been largely debunked, opioid prescribing has continued to fall, as doctors became fearful of being accused of “overprescribing.”

The DEA says the “medical usage” of opioids fell by 10.5% in 2024 alone. The agency expects  that trend to continue, while dismissing claims that its shrinking opioid production quotas have interfered with the practice of medicine. 

“DEA's regulations do not impose restrictions on the amount and the type of medication that licensed practitioners can prescribe. DEA has consistently emphasized and supported the authority of individual practitioners under the CSA to administer, dispense, and prescribe controlled substances for the legitimate treatment of pain within acceptable medical standards,” DEA said. 

3 New Year’s Resolutions on Behalf of Pain Patients

By Crystal Lindell

It’s now 2026, which means I’ve spent too many decades making mostly failed New Year’s resolutions for myself. So this year, I’m not going to bother.

Instead, I have some New Year’s resolutions for other people. Specifically, they’re for people with power, like doctors and healthcare policy makers.

After all, it really seems like they need to make some policy changes, given the current state of things for people in pain. Perhaps they are just waiting for someone to tell them what those changes should be. 

Below is a look at three of my 2026 New Year’s resolutions on behalf of pain patients..

Resolution # 1: Fully Legalize 7-OH and Develop New Edibles

There’s so many conflicting local regulations when it comes to kratom and 7-OH, despite the fact that neither one is as harmful as health officials and lawmakers often claim.

For those unfamiliar, 7-OH is short for 7-hydroxymitragynine, an alkaloid that occurs naturally in kratom in trace amounts. Some kratom vendors now sell concentrated versions of 7-OH to boost its potency as a pain reliever and mood enhancer.

A lot of pain patients find both 7-OH and kratom to be effective at treating chronic pain. And while I am glad that both are still legal in most places in the United States, I would really like to see them fully legalized across the country, as municipalities and states realize just how beneficial these products can be.

I also would really like to see 7-OH vendors come out with some new edible formats, like chocolates, gummies and even seltzer.

I think 7-OH in particular has the potential to help a lot of people who have been denied adequate pain treatment. However, many of them may not be comfortable figuring out where to buy and correctly dose a 7-OH chewable tablet, especially if they are among one of the largest demographic of pain patients: the elderly.  

I think of my grandma trying to get 7-OH tablets at a local smoke shop, or having to figure out how to order them online. Both options are bad. 

Ideally, regular grocery stores and local pharmacies would have a display of low-dose 7-OH chocolates available over-the-counter for pain patients like her.

Resolution # 2: Stop Prescribing Gabapentin and Tramadol for Pain

This would be such a relatively easy change for doctors to make, and there’s so much science to back it up.

In October of 2025, PNN covered a study showing that tramadol is often not effective for chronic pain. And PNN has long been covering how ineffective gabapentin is for most pain conditions.  

However, despite the evidence, doctors still regularly prescribe gabapentin and tramadol for chronic pain. 

It doesn’t have to be that way. Doctors have alternatives that actually work, most notably low-dose hydrocodone. Yes, there are more regulations around that medication, making it more difficult to prescribe. But actually giving pain patients real options shouldn’t be so difficult.  

So, I would like doctors and other healthcare professionals to make it their goal to stop prescribing ineffective medications. Instead, offer pain treatments that actually work. Your patients will thank you.

Resolution # 3: Implement Medicare for All

Yes, I know this one is kind of unrealistic. But that’s what New Year’s magic is all about —  putting whimsical ideas out into the universe with the hope of seeing them come to fruition. 

After all, it can’t happen if we never ask for it.

Unfortunately, as the year starts off, we are actually heading in the opposite direction, with many Americans seeing their health insurance premiums soar or even deciding not to buy coverage. 

But I’m hoping that may be the catalyst we need for the public to start demanding real change. Right now, millions of people are losing their health insurance because the Trump administration ended federal subsidies for coverage under the Affordable Care Act. 

It’s an awful and unnecessary situation that our policy leaders have the power to fix, if only they worked together on the issue.

Every human should have the right to healthcare, and Medicare for All would go a long way to making that happen.

I know a lot of these resolutions probably won’t come to fruition in 2026, but I do think they could realistically happen before we start the next decade. And all of them have the potential to vastly improve the lives of millions of people living with chronic pain.

Happy New Year everyone. May your 2026 be filled with low-pain days, too much joy, and lots of love.

Hip Pain Has Many Causes and Most Don’t Require Surgery

By Charlotte Ganderton and Joshua Heerey

You can feel hip pain at any stage of life, including childhood, young adulthood and the middle years.

This can come as a surprise; since many people associate hip pain with old age. It can strike fear into the hearts of those in their 40s or 50s, who may suddenly wonder if old age – or even a hip replacement – may be on the horizon much sooner than expected.

The good news is only a minority of people with hip pain will have something medically concerning or actually need surgery. Surgery should only be considered after doing a comprehensive rehabilitation exercise program.

There are lots of complex underlying reasons for hip pain, and there may be plenty you can do before you start jumping to conclusions about needing surgery.

Causes of Hip Pain

In young boys and men, a condition known as femoroacetabular impingement syndrome is a common cause of hip pain. This is particularly true for those who play sports (such as soccer) where you need to change direction quickly and often.

This condition is caused by a bigger hip ball (also known as the femoral head) or the hip socket (the acetabulum). This may cause pain at the front or side of the hip. The pain may get worse during movements that involve the knee coming towards the chest (such as a squat) or trending across the middle of the body (such as sitting cross-legged).

In young girls and women, hip dysplasia is particularly common. This happens when the hip socket does not fully cover the ball of the joint. The hip can move too much, and may cause pain at the front, side or back of the hip.

However, excessive hip movement can also be caused when the connective tissue (such as the ligaments and hip capsule) get too elastic or stretchy.

Some people – such as performing artists, yogis and swimmers – may thrive on having more mobility for their artistry and sporting pursuits, but they need to be strong enough to control their excessive motion. Because people with increased mobility are at risk of injury, it is important to maintain hip muscle strength to support the hip joint.

In middle-aged adults and older people, the most common causes of hip pain are osteoarthritis and gluteal tendinopathy.

People with osteoarthritis often experience hip pain and stiffness, and may find it hard to reach down and put on shoes and socks.

People with gluteal tendinopathy might experience pain on the outside of their hip and have problems with lying on their side, climbing stairs or standing on one leg.

My Hip Hurts. How Worried Should I Be?

Well, it’s fundamentally about quality of life.

Does your hip pain make it hard to do social or community activities, perform daily tasks, or stay active? If so, then yes – you’re right to be concerned about your hip pain.

However, most hip conditions can be well managed with non-surgical treatments, such as exercises or stretches prescribed by a physiotherapist, doctor or other health-care professional. You may find you’re soon back to taking those long strolls in the park.

Whether your hip is too stiff or too mobile, start by seeking a thorough clinical examination from a trained and registered doctor or healthcare professional (such as a physiotherapist).

They may ask you to get some scans to help diagnose the cause of your hip pain. In most cases, an X-ray is used to understand the shape of the bones that form the hip joint and check for osteoarthritis.

In some people, an MRI is ordered to get a more detailed understanding of the different components of the hip joint. However, it is important to remember something might show up on an MRI even in people without pain.

Treatment for Hip Pain

Hip pain can often be managed with or without surgery.

If you do end up needing surgery, it’s worth knowing there are lots of different types of surgical treatments. The most common are hip arthroscopy (keyhole surgery) and hip replacement. For many people, though, non-surgical treatments are effective.

These might include adjusting how you exercise or do sport; learning about how to manage symptoms; and muscle strengthening exercises.

In most cases, it’s recommended to try non-surgical treatments for at least three months to see if they help reduce pain and improve hip function before considering surgery.

Whatever you do, stay active. And remember strong bum muscles are important to maintaining healthy hips, so try to find ways to keep your glutes strong.

Charlotte Ganderton, PhD, is a Senior Lecturer in Physiotherapy at RMIT University in Australia. She has received numerous awards for her research and has published papers and presented at national conferences in the musculoskeletal management of the hip and shoulder. 

Joshua Heerey, PhD, is a Physiotherapist and Research Fellow at La Trobe University in Australia. He has published numerous articles examining the diagnosis and treatment of intra-articular hip conditions and is a current member of the International Hip-Related Pain Research Network and Young Athlete’s Hip Research Collaboration.

This article originally appeared in The Conversation and is republished with permission.

The 5 Most Popular PNN Stories of 2025

By Crystal Lindell

Looking back at 2025, there was a lot of news to cover when it came to chronic pain and illness. Access to opioids was again a major concern for our readers, but there was also a lot of interest in the potentially harmful effects of gabapentin.

Below is a look at the top 5 most widely read articles that PNN published in 2025.

We truly appreciate every time you read, comment and share our articles. And we can’t wait to bring you more great coverage in 2026! 

1) Over 15 Million Americans Prescribed Gabapentin Despite Warnings

In September, we covered an analysis by CDC researchers that showed that the use of gabapentin (Neurontin) continued to soar in the United States — usually for chronic pain and other health conditions the drug is not approved to treat. 

Gabapentin is the fifth most prescribed drug in the United States, with prescriptions nearly tripling since 2010, according to findings published in the Annals of Internal Medicine. The number of patients prescribed gabapentin reached 15.5 million in 2024, up from 5.8 million in 2010.

Read the full article here.  

2) Cannabis Use by Older Adults Linked to ‘Younger Brains’ and Improved Cognition

In August, we covered a study that showed that cannabis use by older adults slowed the aging of their brains and may even improve cognitive function.  

An international research team analyzed health data on more than 25,000 adults in the UK, looking at the relationship between cannabis use, aging, and cognitive function. They found that cannabis users had brain characteristics “typically associated with younger brains” and “enhanced cognitive abilities.” 

Read the full article here

3) 6 Things to Try If Your Doctor Won’t Prescribe Opioid Pain Medication

A lot of pain patients find that their doctors are reluctant to prescribe opioids. So in February, I shared six things to try if your physician tells you to go home and take ibuprofen.

The first tip is not to give up. Tell your doctor what poorly treated pain is doing to your life – that you’re unable to work or that you may have to go to the emergency room. Tell the truth and don’t exaggerate, and you just might get them to change their mind.

Another option is to try kratom and/or cannabis. They don’t work for everyone, but many patients say they provide some level of pain relief.  

Read the full article here. 

4) DEA Plans Further Cuts in Oxycodone Supply

In November, we covered the DEA’s plan to cut the supply of oxycodone by more than 6% in 2026, along with marginal reductions in the supply of hydrocodone, morphine and other Schedule II opioids. 

From year-to-year, the cuts may not appear significant. But over the past decade, there has been an historic decline in the nation’s opioid supply. If its current plan is adopted, DEA will have cut the supply of hydrocodone and oxycodone by over 70% since 2014.

The DEA says the “medical usage” of prescription opioids is declining, when in fact the “medical need” for them is actually increasing.

Read the full article here

5) Study Links Gabapentin to Increased Dementia Risk 

In July, we covered how gabapentin (Neurontin) may significantly increase the risk of dementia and cognitive impairment, even for middle-aged patients who only took the nerve medication for six months.

That was according to research published in the Regional Anesthesia & Pain Medicine journal, which looked at health records for more than 26,000 U.S. patients with chronic low back pain.

Researchers found that patients with six months or more of gabapentin use had a 29% higher risk of developing dementia and an 85% higher risk of developing mild cognitive impairment 

Read the full article here.

We hope you enjoyed reading PNN in 2025 and that you found our stories informative and helpful. We look forward to continuing our coverage of chronic pain and other health issues in 2026. 

Unlike many other online news outlets, we don’t hide behind a paywall or charge for subscriptions. PNN depends on reader donations to continue publishing, so please consider making a donation today.

Happy New Year everyone!

The Basic Protocol for Treating Adhesive Arachnoiditis 

By Dr. Forest Tennant

When Arachnoiditis Hope was formed eight years ago, we had enough experience under our belt to know that treatment of adhesive arachnoiditis (AA) required 3 medical components: 

  1. Suppression of inflammation

  2. Regeneration of the cauda equina and arachnoid membrane

  3. Relief of pain 

Our recommended basic protocol has evolved over the past eight years, based on our review of about 2,000 AA cases. This treatment protocol has been consistently successful in treating most AA cases.  

The basic protocol represents our best approach to stop deterioration. Once established, we recommend additional measures in an attempt to permanently reduce pain and neurologic impairments.

The starting treatment protocol:   

Relief of Pain

Choose a short-acting opioid for pain flares and exacerbations.

Options include less potent opioids, such as tramadol, codeine, buprenorphine, and hydrocodone or oxycodone with acetaminophen 

More potent opioids include oxycodone (plain), morphine, fentanyl and hydromorphone

Suppression of Inflammation and Autoimmunity

  • Methylprednisolone 4 mg or dexamethasone 0.5 or 0.75 mg two or three days a week

  • Ketorolac 10 mg with meals 2 days a week or a 15 to 60 mg injection one day a week

There are alternatives to corticosteroids and ketorolac, but they do not appear as consistent or effective.

Regeneration of Cauda Equina and Arachnoid Membrane

Dehydroepiandrosterone (DHEA) 200 mg in AM and PM

Additional Measures

Supportive Diet, Vitamins and Minerals: The basic protocol is supported by a daily protein, low carbohydrate, sugar-restrictive, anti-inflammatory diet (daily fruits and vegetables), plus vitamins C, B-12, D and the minerals, magnesium and selenium.

Spinal Fluid Flow Exercises: Rocking in a chair or gentle bouncing on an indoor trampoline are recommended.

Advanced Treatment: After a person is stabilized on the basic protocol, some additional measures that are designed to permanently reduce pain and symptoms can be added. These include peptide/hormone administration, Epstein-Barr virus eradication, adhesion dissolution, electromagnetic therapy, and central pain therapy.

As we approach the end of 2025 we hope you have received some benefit from our efforts to help those suffering with adhesive arachnoiditis and related conditions.  We will likely start a new bulletin series in 2026.  You may wish to print or download and save some of our bulletins from 2025.

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its research bulletins here.   

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section. 

A Pained Life: What's in a Name?

By Carol Levy

First, we were called “handicapped." It was a wholesale term to paint all those with physical, emotional or intellectual limitations. One inability meant total inability. Often, it was used as an exclusionary term, to mean someone was “less than.”

Eventually, it was realized that handicapped was a demeaning term. So, they changed it to “disabled.” That too was belittling — a word that tended to make us seem less than whole.

Then came physically (or emotionally or intellectually) “challenged.” That sounds better. After all, being challenged just means you have to try harder to meet goals and objectives.

But even that term carries a subtle meaning: we can overcome challenges if we just “try harder” or “do better.” It suggests we are too lazy, too much of a malingerer, and don't want to even try.

There has to be something better. In thinking about this, I had an “Aha!” moment: I am not disabled, I am “unable.”

That seems more appropriate. After all, being unable in one sense does not mean unable in all. "I am unable to answer the phone right now. Please call back later.".

Because of my trigeminal neuralgia, I can't use my eyes for more than 15 -20 minutes without severe pain. I can't tolerate wind or even a slight breeze against the affected side of my face.

But the rest of me is able and willing. It only makes me unable to do things that require the use of my eyes. I am still able to do things that are physically demanding. I can walk, talk, think, exercise, and thankfully take care of myself. That is far from being disabled. 

Others among us may be unable to lift things, clean a room, or even walk. But we can still think, talk, read, and interact with others, even if only on the phone or online.  We are “unable” in part, but able in many other ways.

But, at the end of the day, does the term used to describe those with inabilities really matter? Most healthy people don’t even consider the label, it’s just a way of quickly describing someone.

Quick descriptions, though, lead to stereotypes and misunderstandings. Take, for example, someone parking in a “handicapped” parking spot.

They may have the placard or license plate that gives them permission to park in these spaces, but when they exit their car and start to walk away, another person may object. They’ll start yelling, “You're not handicapped! How dare you park there and take the space away from someone who actually needs it!”

I have had this happen to me. But it’s too hard to explain what trigeminal neuralgia is, and how the wind or even a breeze could set off a pain flare.

Instead, I say, “I do not need to have a cane or wheelchair to be disabled. I may have a heart condition or emphysema or any number of other disorders that make it difficult for me to park farther away from the entrance.”

Looking abashed, if you're lucky, the person walks away.

It would be nice and so much easier, if I could respond by saying “You're right. I am not handicapped in the way you expect me to be. I am unable physically in a way that may be invisible to you, but necessitates my using this spot.”

I keep my fingers crossed, hoping it’s a teachable moment, that this person will understand that “unable” in one sense does not mean unable in all. Maybe, if we're all really lucky, she’ll be able to pass it on.

Carol Jay Levy has lived with trigeminal neuralgia, a chronic facial pain disorder, for over 40 years. She is the author of “A Pained Life, A Chronic Pain Journey.”  Carol is the moderator of the Facebook support group “Women in Pain Awareness.” Her blog “The Pained Life” can be found here.  

On a Scale of 1 to 10…

By Julie Titone

Pain is the most common reason that people see a primary care doctor. If you have chronic pain – the kind that’s stuck around for three months or more – chances are you’ve seen lots of specialists, too. 

You may dread their standard question as much as I do: “On a scale of 1 to 10, how much pain do you feel, with 10 being the worst pain possible?”

I hesitate to answer. If I say 6, will I feel like a whiner? If I say 5, will my pain be taken seriously? 

How would I know if I felt the worst possible pain? 

Are you asking me how much it hurts when I stand or when I sit?

There is value in trying to quantify pain, and many have tried to improve upon the 10-point scale. But pain can never be captured by numeric language or, for that matter, by the English language. Good doctors are less interested in numbers than in how the pain is affecting someone’s life.

This subject is on my mind because of the responses to my column, “Arachnoiditis: My Not-So-Rare Disease.” 

Readers who share my diagnosis of adhesive arachnoiditis told me they appreciated my effort to spread the word about this chronic inflammatory disease. But a few chided me for downplaying how painful arachnoiditis can become. 

Here is what I wrote: “Patients experience lower body numbness and stinging pain that, at its worst, is likened to hot water dripping down the legs. The disease can lead to paralysis and bladder dysfunction.”

I debated which words to use in that paragraph. A litany of misery might cause folks to stop reading, so I kept the descriptive list short. 

Now, in recognition of those who suffer, I will expand upon the kinds of pain reported by arachnoiditis patients:

  • Burning, stabbing, shocking, zapping

  • Buzzing, icy hot, insects crawling under the skin. 

  • Deep aching/boring in the spine. 

  • Pain radiating down the back of the legs. 

  • Vice-like pressure. Cramping. 

  • Pain that increases upon standing or sitting. 

  • Sudden flares triggered by movement. 

  • Widespread burning in the lower body. 

  • Pelvic, abdominal and bladder-related pain. 

  • Unrelenting, throbbing, exhausting pain.

As one woman wrote in an online discussion: “How much can a body take?” 

Some patients would answer that question with suicide.

What makes this all doubly sad is that arachnoiditis often begins when people seek relief, via injections or surgery, from another source of pain.

So far, my own arachnoiditis is not debilitating. I get modest relief from medicines, movement and massage. Distraction helps. If you need advice on the best ice packs and seat cushions, I’m your gal.

Chronic pain plagues an estimated 20 to 30 percent of people in the world at any given time. The cliché goes that misery loves company. I don’t love it, but that massive company could work in my favor someday.

Researchers have 2 billion reasons to investigate pain treatment and prevention. As the secrets of neural pathways are unlocked, the knowledge is bound to benefit those of us with arachnoiditis.

Julie Titone is a former newspaper journalist who also worked in academic and library communications. She is retired and lives in Everett, Washington. Julie’s website is julietitone.weebly.com.

This column first appeared in Julie’s Substack blog and is republished with permission. 

Congress Went Home for Holidays, Leaving Millions to Face Rising Healthcare Costs

By Robert Applebaum

Dec. 15, 2025 – the deadline for enrolling in a marketplace plan through the Affordable Care Act for 2026 – came and went without an agreement on the federal subsidies that kept ACA plans more affordable for many Americans. 

Despite a last-ditch attempt in the House to extend ACA subsidies, with Congress adjourning for the year on Dec. 19, it’s looking almost certain that Americans relying on ACA subsidies will face a steep increase in health care costs in 2026.

As a gerontologist who studies the U.S. health care system, I’m aware that disagreements about health care in America have a long history. The main bone of contention is whether providing health care is the responsibility of the government, or of individuals or their employers.

The ACA, passed in 2010 as the country’s first major piece of health legislation since the passage of Medicare and Medicaid in 1965, represents one more chapter in that long-standing debate. That debate explains why the health law has fueled so much political divisiveness – including a standoff that spurred a record-breaking 43-day-long government shutdown, which began on Oct. 1, 2025.

In my view, regardless of how Congress resolves, or doesn’t resolve, the current dispute over ACA subsidies, a durable U.S. health care policy will remain out of reach until lawmakers address the core question of who should shoulder the cost of health care.

The ACA’s Roots

In the years before the ACA’s passage, some 49 million Americans – 15% of the population – lacked health insurance. This number had been rising in the wake of the 2008 recession. That’s because the majority of Americans ages 18 to 64 with health insurance receive their health benefits through their employer. In the 2008 downturn, people who lost their jobs basically lost their health care coverage.

For those who believed government had a primary role in providing health insurance for its citizens, the growing number of people lacking coverage hit a crisis point that required an intervention. Those who place responsibility on individuals and employers saw the ACA as perversion of the government’s purpose. The political parties could find no common ground – and this challenge continues.

The major goal of the ACA was to reduce the number of uninsured Americans by about 30 million people, or to about 3% of the U.S. population. It got about halfway there: Today, about 26 million Americans, or 8%, are uninsured, though this number fluctuates based on changes in the economy and federal and state policy.

Health Insurance for All?

The ACA implemented an array of strategies to accomplish this goal. Some were popular, such as allowing parents to keep their kids on their family insurance until age 26. Some were unpopular, such as the mandate that everyone must have insurance.

But two strategies in particular had the biggest impact on the number of uninsured. One was expanding the Medicaid program to include workers whose income was below 138% of the poverty line. The other was providing subsidies to people with low and moderate incomes that could help them buy health insurance through the ACA marketplace, a state or federal health exchange through which consumers could choose health insurance plans.

Medicaid expansion was controversial from the start. Originally, the ACA mandated it for all states, but the Supreme Court eventually ruled that it was up to each state, not the federal government, to decide whether to do so. As of December 2025, 40 states and the District of Columbia have implemented Medicaid expansion, insuring about 20 million Americans.

Meanwhile, the marketplace subsidies, which were designed to help people who were working but could not access an employer-based health plan, were not especially contentious early on. Everyone receiving a subsidy was required to contribute to their insurance plan’s monthly premium. People earning US$18,000 or less annually, which in 2010 was 115% of the income threshold set by the federal government as poverty level, contributed 2.1% of their plan’s cost, and those earning $60,240, which was 400% of the federal poverty level, contributed 10%. People making more than that were not eligible for subsidies at all.

In 2021, legislation passed by the Biden administration to stave off the economic impact of the COVID-19 pandemic increased the subsidy that people could receive. The law eliminated premiums entirely for the lowest income people and reduced the cost for those earning more. And, unlike before, people making more than 400% of the federal poverty level – about 10% of marketplace enrollees – could also get a subsidy.

These pandemic-era subsidies are set to expire at the end of 2025.

Cost vs Coverage

If the COVID-19-era subsidies expire, health care costs would increase substantially for most consumers, as ACA subsidies return to their original levels. So someone making $45,000 annually will now need to pay $360 a month for health insurance, increasing their payment by 74%, or $153 monthly. What’s more, these changes come on top of price hikes to insurance plans themselves, which are estimated to increase by about 18% in 2026.

With these two factors combined, many ACA marketplace users could see their health insurance cost rise more than 100%. Some proponents of extending COVID-19-era subsidies contend that the rollback will result in an estimated 6 million to 7 million people leaving the ACA marketplace and that some 5 million of these Americans could become uninsured in 2026.

Policies in the tax and spending package signed into law by President Donald Trump in July 2025 are amplifying the challenge of keeping Americans insured. The Congressional Budget Office projects that the Medicaid cuts alone, stipulated in the package, may result in more than 7 million people becoming uninsured. Combined with other policy changes outlined in the law and the rollback of the ACA subsidies, that number could hit 16 million by 2034 – essentially wiping out the majority of gains in health insurance coverage that the ACA achieved since 2010.

Subsidy Downsides

These enhanced ACA subsidies are so divisive now in part because they have dramatically driven up the federal government’s health care bill. Between 2021 and 2024, the number of people receiving subsidies doubled – resulting in many more people having health insurance, but also increasing federal ACA expenditures.

In 2025, almost 22 million Americans who purchased a marketplace plan received a federal subsidy to help with the costs, up from 9.2 million in 2020 – a 137% increase.

Those who oppose the extension counter that the subsidies cost the government too much and fund high earners who don’t need government support – and that temporary emergencies, even ones as serious as a pandemic, should not result in permanent changes.

Another critique is that employers are using the ACA to reduce their responsibility for employee coverage. Under the ACA, employers with more than 50 employees must provide health insurance, but for companies with fewer employers, that requirement is optional.

In 2010, 92% of employers with 25 to 49 workers offered health insurance, but by 2025, that proportion had dropped to 64%, suggesting that companies of this size are allowing the ACA to cover their employees.

Dueling Solutions

The U.S. has the most expensive health care system in the world by far. The projected increase in the number of uninsured people over the next 10 years could result in even higher costs, as fewer people get preventive care and delayed health care interventions, ultimately leading to more complex medical care

Federal policy clearly shapes health insurance coverage, but state-level policies play a role too. Nationally, about 8% of people under age 65 were uninsured in 2023, yet that rate varied widely – from 3% in Massachusetts to 18.6% in Texas. States under Republican leadership on average have a higher percentage of uninsured people than do those under Democratic leadership, mirroring the political differences driving the national debate over who is responsible for shouldering the costs of health care.

With dueling ideologies come dueling solutions. For those who believe that the government is responsible for the health of its citizens, expanding health insurance coverage and financing this expansion through taxes presents a clear approach. For those who say the burden should fall on individuals, reliance on the free market drives the fix – on the premise that competition between health insurers and providers offers a more effective way to solve the cost challenges than a government intervention.

Without finding resolution on this core issue, the U.S. will likely still be embroiled in this same debate for years, if not decades, to come.

Robert Applebaum, PhD,  is a Senior Research Scholar in the Department of Sociology and Gerontology at Miami University. He is also Director of the Ohio Long-Term Care Research Project and Senior Research Scholar at the Scripps Gerontology Center.

This article originally appeared in The Conversation and is republished with permission.


My Christmas Wishes for Pain Patients

By Crystal Lindell

With Christmas spirit in the air, and the hope of the New Year close behind, it seems only appropriate to make some holiday wishes for all my fellow pain patients.

Here are my wishes for people in pain:

More low-pain days than not. Easy opioid prescription refills. Clothes that don’t hurt to wear. Supportive family that always believes you and never judges you.

The ability to use a cane, the possibility of not needing it, and the wisdom to know the difference.

I wish for you a sweet pet to cuddle up in your lap whenever you can’t get off the couch. Money that comes in more than it goes out. And steady weather, so that the barometric pressure doesn’t increase your pain.

I wish that every book you read to get through a pain flare takes you to a new world where your pain isn’t as bad.

I wish for you a doctor who takes you seriously and prescribes you medications that actually work. Health insurance that actually covers all of your medical expenses. And a pharmacist who actually believes you.

I wish you more strength that you need to keep going when the pain is really trying to make you stop. And the ability to keep hope alive even when you’d rather be dead.

If you’re seeking answers and a diagnosis, I hope you find both. 

If you’re seeking a romantic partner, I hope they find you. 

If you’re just seeking a good TV show to watch on bad pain days, I hope you find one with lots of seasons. Hopefully, it’s on one of the streaming services you already subscribe to!

May your naps always rejuvenate you, your medications always kick in quickly, and your shoes always be comfortable.

But most of all, my wish for you is that your pain goes away. I really do.

Sadly, like my body, my wishes don’t always work so well. They only rarely come true. 

So, if your pain refuses to leave, I wish only that you know that this world needs you in it, and that it’s vitally important that you keep going. There are still so many things left for you to see and do and accomplish. 

Merry Christmas dear pain patient, and hopefully a very happy New Year – or at least a survivable year ahead.

Review Finds THC More Effective Than CBD for Chronic Pain

By Pat Anson

An updated systematic review found that cannabis products with relatively high levels of THC (tetrahydrocannabinol) may provide small improvements in chronic pain; while those containing high levels of CBD (cannabidiol) and little or no THC had minimal effect on pain.

Researchers at the Pacific Northwest Evidence-based Practice Center at Oregon Health & Science University reviewed 25 short-term cannabis studies involving over 2,300 patients with chronic pain. Their findings are published in the Annals of Internal Medicine. 

CBD-based gummies, tablets, oils and other products have long been marketed for various health issues, but researchers say they demonstrated almost no improvement in managing pain. 

“This may be surprising to people,” said lead author Roger Chou, MD, in a press release. “Conventional wisdom was that CBD was promising because it doesn’t have euphoric effects like THC and it was thought to have medicinal properties. But, at least in our analysis, it didn’t have an effect on pain.” 

Chou, who was lead author of the controversial 2016 CDC opioid guideline and its 2022 update, said the small improvement in pain was on the order of a half point to a point on the zero-to-10 pain scale. While providing modest pain relief, THC-based products also had a higher risk of side effects, such as dizziness, sedation and nausea.   

There are several caveats to the review which make it unhelpful, at best, in determining whether THC or CBD are effective pain relievers. 

One, many of the clinical trials were deemed to be biased or of low quality. They mostly involved patients with chronic neuropathic pain, which means they don’t necessarily apply to patients with other types of pain.

Second, most of the studies involved pharmaceutical-grade cannabis-based medicines, such as dronabinol and nabilone, which are approved for nausea, vomiting and as an appetite stimulant. None of them are approved for pain relief.  

Third, those pharmaceutical medicines are based on synthetic THC, not plant-derived THC or CBD. So basically, the researchers studied products that most cannabis consumers don’t use, which makes the overall findings misleading.

“This raises critical questions about generalizability: Can findings from standardized formulations inform real-world use of diverse, cannabis-derived, state-regulated products?” asks Ziva Cooper, PhD, from the UCLA Center for Cannabis and Cannabinoids, in an editorial also published in the Annals of Internal Medicine.   

Copper says the review demonstrates the need for better evidence and less reliance on clinical trials. The inclusion of observational studies and patient reviews of products obtained in dispensaries would better capture real-time evidence of current cannabis use and outcomes. 

“There are opportunities for novel approaches to understand cannabis-related health effects. Rigorous randomized controlled trials (RCTs) are the gold standard for determining the safety and efficacy of cannabis and cannabinoids for therapeutic end points,” Cooper wrote. 

“Yet, these studies are resource-intensive, challenging due to federal regulations, and slow to adapt to a rapidly evolving marketplace and patient behavior. Expanding the scope of study designs to consider complementary strategies is urgently needed.”

Chou says the wide variety of cannabis products on the market makes drawing conclusions about their effectiveness difficult.

“It’s complicated because cannabis products are complicated,” he said. “It’s not like taking a standardized dose of ibuprofen, for example. Cannabis is derived from a plant and has multiple chemicals in addition to THC and CBD that may have additional properties depending on where it’s grown, how it’s cultivated and ultimately prepared for sale.”  

Better cannabis research is one of the reasons the Trump Administration is moving to complete the process of reclassifying cannabis from a Schedule I controlled substance to a Schedule III drug with accepted medical uses.

Because cannabis has long been illegal under federal law, it has stifled research into its health benefits, leaving patients and doctors in the dark on its potential uses. This review does nothing to shine a light on the issue.  

Could PEMF Therapy Recharge Your Health?

By Madora Pennington 

I tend to be skeptical of any health treatment that sounds a bit “woo-woo.” After all, I don’t want to waste my resources on something that doesn’t work or might only be placebo.

But after experiencing so much benefit from stimulating my vagus nerve with a neuromodulation device, I wondered what other bioelectric medicine I could benefit from.

Perhaps you have heard of PEMF. It stands for pulsed electromagnetic field therapy. Like a TENS, ultrasound, or vagus nerve stimulator, it seeks to treat the body using electric currents.

Most PEMF devices are a mat for laying on, or sometimes a metal coil that is held or placed on an area of the body. A PEMF sends magnetic energy through the body or part of it.

Similarly, the depression treatment Transcranial Magnetic Stimulation (TMS) uses high intensity magnetic pulses to penetrate the skull to shift the brain out of states like depression, anxiety, or pain.

PEMF technology has been around since at least the 1970s. It’s first FDA approval came in 1979 for the treatment of non-healing bone fractures.

PEMF therapy works because the body responds to external forces. For example, bones get stronger from stress (think tennis or running), which triggers an electrical charge in the body that causes bone remodeling.

The pulsating low magnetic frequency of PEMF has a positive effect on cellular and biophysical systems, beyond just bones. A damaged or unhealthy cell may have its electrical charge disrupted. PEMF treatment increases cellular energy and improves blood flow, accelerating cell regeneration and tissue repair, acting as a sort of battery charger to cells.

Because collagen responds to forces like bones do, PEMF therapy helps tendons, ligaments, and wounds heal. It can also reduce low back pain and pain from osteoarthritis. Sessions on a PEMF can even increase cartilage, the cushioning tissue in joints.

I purchased the Hoolest MiniMax PEMF because I liked their vagus nerve stimulator. This is the only PEMF device I have tried, so I can’t compare it to others.

The Hoolest PEMF aims to be a clinical level device for the home user. Unfortunately, the MiniMax is not inexpensive, and costs thousands of dollars.

The founder of Hoolest says it takes powerful machinery to put energy through the entire body.

“A PEMF can activate and strengthen the entire network of the nervous system at once, while a vagus nerve stimulator takes smaller areas, just one section,” Nick Hool told me.

Hool advises using it frequently. Like exercise, it takes consistent application to get the most benefit.

My PEMF is bulky and noisy, making weird sounds like an MRI, another magnetic technology. Nonetheless, it is deeply soothing and relaxing and quickly became part of my daily routine.

Placing the coil on old injuries feels just wonderful. After some weeks of using it, my tolerance for exercise increased because the PEMF reduced post-exercise aches and soreness. I noticed I was sleeping very deeply. Overall, my mood was consistently optimistic and relaxed.

On Thanksgiving, a few of my guests took turns spending a half hour on my PEMF mat, after I jokingly promised it would cure anything. All said they felt deeply relaxed from it into the next day.

For the chronically ill, stimulating the body with magnetic pulses may be particularly helpful in ways that medications or surgeries are not. The pulsating magnetic frequencies of a PEMF promote homeostasis, the ideal state of balance in the body.

In the aftermath of severe illness or injury, symptoms can linger when the body is not properly regulating inflammatory processes. Immune cells can become inappropriately activated. All of this prevents tissue healing, which can result in chronic pain.

Time spent on a good PEMF device can re-regulate these off-kilter inflammatory and immune responses. This may clear up brain fog and alleviate chronic fatigue.

In the case of chronic pain, a PEMF may improve faulty signals that are transmitting too many pain messages to the brain. A PEMF device can also stimulate deeper branches of the vagus nerve that external stimulators applied to the skin cannot reach.

PEMF devices vary wildly in their specifications and so does their effectiveness. Studies often comment on the lack of uniformity in PEMF devices, which makes studying their results less consistent. Standard PEMF protocols would make studies more reliable.

Most insurers do not cover PEMF therapy, and consider it “experimental, investigational, or uproven,” although some specific FDA-approved uses, such as bone healing, might be exceptions.

Pregnant women and growing children should not use a PEMF. People with implanted devices like pacemakers should not use a PEMF, as it may make them malfunction.